@TinaWitte
Joined November 2011
  • Tweets6.1K
  • Following671
  • Followers196
59Media
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset biospace.com/business/roches…

Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset

Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.

biospace.com
7
US approves Roche's Gazyva to prevent nephrotic syndrome relapses firstwordpharma.com/story/81… via @fwpharma

US approves Roche's Gazyva to prevent nephrotic syndrome relapses

Roche's Gazyva (obinutuzumab) has secured its second FDA approval in kidney di...

firstwordpharma.com
17
Elevar gets US nod for FGFR2-targeted cholangiocarcinoma drug firstwordpharma.com/story/80… via @fwpharma

Elevar gets US nod for FGFR2-targeted cholangiocarcinoma drug

The FDA has greenlit Elevar Therapeutics' Lyrfigtu (lirafugratinib) for adults...

firstwordpharma.com
9
Flagship wins $47M Department of War award for AI-informed countermeasures firstwordpharma.com/story/80… via @fwpharma

Flagship wins $47M Department of War award for AI-informed countermeasures

The Trump administration's recently rebranded Department of War (DoW) awarded ...

firstwordpharma.com
11
Lilly taps InnoCare in $3.3B drug discovery deal firstwordpharma.com/story/80… via @fwpharma

Lilly taps InnoCare in $3.3B drug discovery deal

Eli Lilly inked a research collaboration and licensing pact potentially worth ...

firstwordpharma.com
11
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight biopharmadive.com/news/wclc-… via @BioPharmaDive

WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight

The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

biopharmadive.com
56
GSK makes $750M bet on Chimagen's trispecific T cell-engager for myeloma firstwordpharma.com/story/79… via @fwpharma

GSK makes $750M bet on Chimagen's trispecific T cell-engager for myeloma

GSK said Tuesday it will acquire an experimental trispecific T cell-engager (T...

firstwordpharma.com
1
32
WCLC26: Enhertu's PFS lung cancer win comes with an OS question mark firstwordpharma.com/story/79… via @fwpharma

WCLC26: Enhertu's PFS lung cancer win comes with an OS question mark

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has delivered ...

firstwordpharma.com
44
‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it fiercebiotech.com/biotech/ne…

‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it

As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.  | As the hype around the vast medical potential of GLP-1 drugs...

fiercebiotech.com
8
Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Drive... prn.to/4r2V8vh

Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a...

/PRNewswire/ -- Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed...

prnewswire.com
24
Beeline flies into phase 3 as oral lupus drug soars past placebo fiercebiotech.com/biotech/be…

Beeline flies into phase 3 as oral lupus drug soars past placebo

A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus. | A phase 2 trial of Beeline Medicines’...

fiercebiotech.com
15
Novartis' del-desiran stumbles in Phase III myotonic dystrophy study; shares sink firstwordpharma.com/story/79… via @fwpharma

Novartis' del-desiran stumbles in Phase III myotonic dystrophy study; shares sink

Novartis said Tuesday a Phase III study evaluating delpacibart etedesiran (del...

firstwordpharma.com
24
Ionis Pharma's drug becomes first FDA-approved treatment for rare brain disorder reuters.com/legal/litigation…

Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose

Ionis Pharmaceuticals ‌said on Friday it would price its newly approved therapy to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the injectable ​drug, making it the...

reuters.com
11
Trump strikes new drug pricing deals with nine midsized drugmakers cnb.cx/4h2cKnt

Trump strikes new drug pricing deals with nine midsized drugmakers

The string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.

cnbc.com
10
Spyre says its anti-TL1A works in rheumatoid arthritis, but still falls short in Phase II firstwordpharma.com/story/79… via @fwpharma

Spyre says its anti-TL1A works in rheumatoid arthritis, but still falls short in Phase II

Spyre Therapeutics' stock was down about 14% Wednesday after a topline readout...

firstwordpharma.com
20
Amgen, AstraZeneca score with Tezspire; can they take on Dupixent? msn.com/en-us/news/other/amg…
45
Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal biopharmadive.com/news/bioha… via @BioPharmaDive

Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal

Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.

biopharmadive.com
22
FDA approves new pancreatic cancer drug expected to usher in new era of treatment statnews.com/2026/08/26/panc… via @statnews

FDA approves new pancreatic cancer drug expected to usher in new era of treatment

The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.

statnews.com
27
FDA approves a new blood test to detect signs of Alzheimer’s washingtonpost.com/health/20…

FDA approves a new blood test to detect signs of Alzheimer’s

The test is not meant for routine screening but can be pivotal for a diagnosis when cognitive problems are causing doctors to suspect the disease.

washingtonpost.com
11
Massachusetts Biopharma Sees Strong Resurgence of Capital Even as Workforce Numbers Lag - MassBio massbio.org/news/recent-news…

Massachusetts Biopharma Sees Strong Resurgence of Capital Even as Workforce Numbers Lag - MassBio

MassBio 2026 Industry Snapshot highlights renewed opportunity with funding and exits returning to the Commonwealth Challenges of declining employment, weaker seed rounds and intensifying global...

massbio.org
10
Load more